Pfizer 100% effective in South African variant trial
The Pfizer-BioNTech vaccine is '100% effective' according to the latest results
As per an official statement, Pfizer and BioNTech have confirmed their vaccine is "100% effective in preventing severe disease" and "in preventing COVID-19 cases in South Africa, where the B.1.351 lineage [variant] is prevalent".
The pivotal third stage study was completed on the 13th of March and the finding were extremely positive. Of "927 confirmed symptomatic cases of COVID-19", it was found that the BNT162b2 vaccine "91.3% efficacy" among already infected patients.
Furthermore, it offers "100% effectiveness against diseases as defined by the Centers for Disease Control and Prevention (CDC)" and "95.3% effective against severe COVID-19 as defined by the U.S. Food and Drug Administration (FDA)"
These results were taken from people who had received their second dose of the vaccine anywhere from in the last seven days, all the way up to six months. The safety data of the study has also been collected from more than 12,000 willing, vaccinated participants, all of which had to follow up within six months to confirm favourable safety and the tolerability of the treatment.
Full analysis of the study can be found in the link above, as well as a press release from Business Wire. Within it are further details including:
- Confirmation of the vaccine procedure's safety, evaluated by more than 44,000 participants of 16 years+
- The results of 850 cases of COVID-19 in the placebo group
- The vaccine's approval for use under an Emergency Use Authorization (EUA)
- Any adverse reactions or side-effects in participants, such as fatigue (62.9%), headache (55.1%), muscle pain etc.
Read the comprehensive report to find out the full details.